New Delhi, July 18, 2016
Some of the key highlights are:
– The IPM grew at 13% as of on MAT June 2016
– The IPM was valued at Rs. 107,019 crores and the retail sector was valued at Rs.89,784 crores as of MAT June 2016
– All therapies have seen a dip since February 2016. However, GI (Gastro Intestinal) has shown a growth in June 2016 over May 2016
– Respiratory is the largest affected market by the ban with 71% of the value of banned drugs being contributed by 6 molecule combinations. However, Dextromethorphan + Chlorpheniramine combinations and Bromhexine combinations have shown improved growth in June 2016
Corporate Comm India(CCI Newswire)
